Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
about
Teriparatide for osteoporosis: importance of the full courseBone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMAModulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal OsteoporosisNovel advances in the treatment of osteoporosis.Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.Profile of romosozumab and its potential in the management of osteoporosis.Constructing the toolbox: Patient-specific genetic factors of altered fracture healingAbaloparatide: a new anabolic therapy on the horizon.Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model.Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study.Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.Osteoporosis therapeutics: recent developments at ASBMREffect of Teriparatide on Bone Formation in the Human Femoral Neck.Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation.Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.Emerging drugs for osteoporosis.Bone markers and osteoporosis therapy.Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.Co-administration of antiresorptive and anabolic agents: a missed opportunity.Short-term and long-term effects of osteoporosis therapies.Osteoporosis in the adult solid organ transplant population: underlying mechanisms and available treatment options.New anabolic therapies for osteoporosis.Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases.Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.Using Osteoporosis Therapies in Combination.Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.Efficacy, effectiveness and side effects of medications used to prevent fractures.Anabolic treatment for osteoporosis: teriparatide.Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.Monoclonal antibodies for treating osteoporosis.
P2860
Q26768410-1ECDAC9E-1CE3-4877-A7B7-4B8F2E722624Q26775158-C7DB7B71-DEB0-445A-BA70-1E16519D1B72Q27022580-2C8BB51B-23D8-4408-B154-8BE272FA1516Q30248319-8C497FD2-C778-4ADB-BD52-72C3DE3542ACQ30978614-78975AC4-D9B1-4ECC-B1DB-B9B7C3AAD9FFQ31056665-C67B37DD-2E5E-4206-BC56-087E0AAEF586Q33570303-0D4E7CBF-0802-4CBD-AE83-885EFC7B95F8Q33570337-6F9D62FD-3505-40D2-ACCB-5A2157838A92Q33596475-21135D10-D54E-48B0-A186-4B73C7B2A536Q34794967-98B64DBF-38BE-422A-88BD-80985453E55DQ35575640-4A713BC3-809C-4425-ADCA-035234A2C728Q36118302-E3FDFADF-5043-4BF5-8D66-DFCBE460B211Q36400219-19C21965-34A7-43D6-89D9-CA62081BF6AFQ36408112-195AAFBF-A3D1-4C6E-BDD7-556CD84E6521Q36448678-0B0BFFEA-64D3-443B-8ACA-46BC18B5B523Q36935517-E9A15843-BF97-47D1-B93C-7E91655B12AFQ37421054-A08FF14B-F8B5-4385-909E-867F6444E878Q37580945-A7C6F3F3-2560-498B-9F52-40545584B8B6Q37661855-A5622000-D353-4CE2-A64C-AD0274A038D4Q38221767-230DA522-32DD-4C98-897B-B59063D7E1B9Q38226342-744A11C1-1565-4C06-888B-C4E3FD3A8C49Q38244170-69165D0F-D878-4716-A59C-1E904B5EB1BBQ38262303-3961B40E-2E9C-4634-A69E-216248DFC9D6Q38367370-DA2F062D-66F9-45F8-99B3-1DDFEE4A975FQ38473594-D0AA37AA-FFA9-4B36-85F2-F24230BCC189Q38609466-7219C180-30AE-421B-A7F3-A703BA511959Q38646406-FFCD50A4-FDE3-4844-A8A9-8DD9100725EFQ38819059-C11EBA9F-CDD6-4856-9E15-446DC171079AQ38824663-ADB22843-D70D-477D-B9DB-A535DD686987Q39035413-95071534-C2DC-4044-869F-AA3977895158Q39183207-85FD15E5-142D-4955-AC34-6D68ED74B738Q39283452-F9BC180A-D550-4C32-BA2B-DFF917D8DD33Q39408210-8CE24CFF-7A1E-47F0-B233-C4C292A15A70Q39967346-DA4DFE66-8838-4450-B60B-B405E4F75E69Q40437923-88CE2412-C6CA-4FFC-AAF7-AFB6481FF5ABQ41704607-F924C074-3A8A-46D5-92C7-48F06DECFE7AQ47163541-E4049FDD-DF9C-4E17-8408-34606AB7A436Q47232860-6D7417A6-51F9-443A-978A-C17153E8BE15Q47428797-E75DE5A1-81C1-4492-A2DD-3A27944E4FEDQ47638169-FC0B2108-5D0F-4469-89A9-A50031128FFB
P2860
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Two years of Denosumab and ter ...... a randomized controlled trial.
@ast
Two years of Denosumab and ter ...... a randomized controlled trial.
@en
type
label
Two years of Denosumab and ter ...... a randomized controlled trial.
@ast
Two years of Denosumab and ter ...... a randomized controlled trial.
@en
prefLabel
Two years of Denosumab and ter ...... a randomized controlled trial.
@ast
Two years of Denosumab and ter ...... a randomized controlled trial.
@en
P2093
P2860
P356
P1476
Two years of Denosumab and ter ...... a randomized controlled trial
@en
P2093
Alexander V Uihlein
Benjamin Z Leder
Joy N Tsai
Katelyn Foley
Robert M Neer
P2860
P304
P356
10.1210/JC.2013-4440
P407
P577
2014-02-11T00:00:00Z